<DOC>
	<DOC>NCT00851643</DOC>
	<brief_summary>This study will examine the safety and tolerability of octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine formulated with amorphous aluminum hydroxysulfate (AAHS) and ISCOMATRIXâ„¢ (IMX). Reviews of safety and tolerability will be used to select the dose(s) of IMX for further studies of the octavalent HPV L1 VLP vaccine.</brief_summary>
	<brief_title>Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)</brief_title>
	<detailed_description>The study was performed in 2 staggered phases, Phase A and Phase B. In Phase A, participants were randomized to qHPV, Octavalent HPV with 15 mcg IMX/AAHS, or Octavalent HPV with 30 mcg IMX/AAHS. After the safety for Phase A was reviewed, Phase B was initiated. In Phase B, participants were randomized to qHPV, Octavalent HPV with 60 mcg IMX/AAHS or Octavalent HPV with 120 mcg IMX/AAHS.</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant is in good physical health Participant has had a lifetime history of 0 to 4 sexual partners Females between 18to24 years Participant has a history of abnormal Pap test Participant has a history of positive test for HPV Participant has a history of recent or ongoing alcohol or drug abuse Participant is immunocompromised or has an autoimmune condition Participant has received immunosuppressive therapy within a year of screening Participant has previously received an HPV vaccine Participant is pregnant Participant has a history of external genital/vaginal warts Participant is currently enrolled in a clinical trial Participant has a history of a severe allergic reaction that required medical attention</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>